OncoMatch/Clinical Trials/NCT06456359
Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell Tumor
Is NCT06456359 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Signifor for desmoplastic small round cell tumor.
Treatment: Signifor — PAMSARC is a non-commercial interventional Phase 2 clinical trial of academic research institutions, with its primary goal being to improve medical treatment of fusion driven Desmoplastic small round cell tumor (DSRCT) and Synovial sarcoma (SySa) in young adults and adolsecents with male predominance. Current management of DSRCT and SySa includes chemotherapy, radiation and aggressive cytoreductive surgery. Despite advances in multimodal therapy, outcomes remain poor with frequent disease recurrence and very limited options for patients with advanced disease. Selected somatostatin receptor (SSTR) family members, i.e., SSTR2, SSTR3 and SSTR5, are frequently overexpressed in DSRCT and SySa, providing the rationale for treatment with somatostatin analogues (SSA). Pasireotide is a SSA with high affinity for SSTR1, -2, -3, and -5 and is approved for the treatment of Cushing's disease and acromegaly and has also shown activity in other cancers. In patients with advanced stage DSRCT and SySa, conventional chemotherapeutic approaches frequently lead to disease response, however, the duration of progression-free time after chemotherapy is short. The targeted approach with pasireotide after initial intensive multimodal treatment may have the potential to significantly improve outcome.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Sarcoma
Biomarker criteria
Required: SSTR2 high mrna expression (high)
Required: SSTR3 high mrna expression (high)
Required: SSTR5 high mrna expression (high)
Disease stage
Required: Stage ANY STAGE
Demographics
Prior therapy
Must have received: chemotherapy
Time from last chemotherapy (at least 2 chemotherapy cycles) to enrollment <8 weeks
Cannot have received: somatostatin analog
Prior treatment with somatostatin analog
Lab requirements
Blood counts
Hemoglobin ≥ 10 g/dl; Neutrophil count ≥ 1,500/mm3; Platelet count ≥ 100,000/µl
Kidney function
Serum creatinine ≤ 1.5 mg/dl or creatinine clearance ≥ 51 ml/min (Crockroft-Gault)
Liver function
Bilirubin ≤ 1.5 x ULN; ALT and AST ≤ 2.5 x ULN; Alkaline phosphatase ≤ 2.5 x ULN; Albumin ≥ 25 g/l
Adequate bone marrow, renal, and hepatic function defined by laboratory tests within 14 days prior to study treatment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06456359 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior somatostatin analog disqualifies patients from enrollment.
Does this trial require SSTR2?
Yes, SSTR2 high mrna expression is a required biomarker for enrollment.
Does this trial require SSTR3?
Yes, SSTR3 high mrna expression is a required biomarker for enrollment.
Does this trial require SSTR5?
Yes, SSTR5 high mrna expression is a required biomarker for enrollment.
What disease stage is eligible?
Stage ANY STAGE is required.
Is there an age limit?
Yes. Patients must be 50 years or younger and at least 13 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages